# Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

> **NCT02980510** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 219 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil
- **DRUG:** Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan

## Key facts

- **NCT ID:** NCT02980510
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-12
- **Primary completion:** 2025-12
- **Final completion:** 2026-01
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980510, "Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02980510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*